Enanta Pharmaceuticals has seen its stock more than double, despite a Phase II respiratory syncytial virus (RSV) trial failing to meet its primary endpoint. The Phase IIb RSVHR study (NCT05568706) ...

Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults. The Watertown, ...

A phase 2b trial of Enanta Pharmaceuticals’ respiratory syncytial virus (RSV) drug candidate has missed its primary endpoint. But, with other analyses generating signs of efficacy, the biotech made ...

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants, with recent global estimates indicating that RSV causes tens of millions of lower respiratory tract infections and ...

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory syncytial virus (RSV) vaccine reduced RSV infections and RSV-related ...

RSV vaccines showed initial high effectiveness, but protection decreased over 18 months, especially in immunocompromised individuals. The study used VHA data to evaluate vaccine effectiveness in ...